CatalystAlertBeta

Briefing Calendar News IPOs Opportunities Companies Compare Analytics Watchlist Learn

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Short Interest
Smart Money
Biotech Glossary

Legal

About
ML Track Record
Privacy
Terms
Cookies

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

Follow Us

⚠️ Important Legal Disclaimer

Not Financial Advice: CatalystAlert is an informational platform only. We are NOT a registered investment advisor, broker, or dealer. The information provided on this website does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and you should not treat any of the website's content as such.

No Guarantees: All predictions, probability scores, and analyses are based on historical data and machine learning models. Past performance does NOT guarantee future results. Biotech investing is extremely high-risk and you may lose your entire investment.

Data Accuracy: While we strive for accuracy, data may be incomplete, delayed, or contain errors. We aggregate data from third-party sources (FDA, SEC, ClinicalTrials.gov) and are not responsible for their accuracy. Always verify information with official sources before making any decisions.

Your Responsibility: You are solely responsible for your investment decisions. Consult a qualified financial advisor before investing. CatalystAlert and its operators accept no liability for any losses incurred from using this platform.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Home Calendar News Learn Account

Palbociclib - Phase 3 | PFE Pipeline | CatalystAlert

Palbociclib

Phase 3

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

10mo

PFEPhase 2$142.7B

Palbociclib Phase 2 Results Expected

Palbociclib• Breast Cancer35

Dec 31Estimated

00%

Competitive Landscape

11 competitors in Breast Cancer

RHHBYtrastuzumab (Herceptin®)

PBYICapecitabine

PBYIvinorelbine

PBYITemsirolimus

View Full Landscape

Drug Information

Target Indication

Breast Cancer

Clinical Trial

Last updated: 12/30/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/9/2016

Ibrance

Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Healthcare•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Cyclosporine APhase 3

Renal Transplantation

Insulin LisproPhase 3

Diabetes Mellitus

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline